Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 4/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17976777 | 0.90 | S1PR1 (0.40) | S1PR1S1PR3S1PR2S1PR5PLA2G4A | |
| SCHEMBL17972403 | 0.88 | PLA2G2A (0.45) | PLA2G2APLA2G4A | |
| SCHEMBL15948704 | 0.88 | EPHX1 (0.35) | PLA2G2AEPHX1 | |
| SCHEMBL15948706 | 0.82 | EPHX1 (0.37) | EPHX1 | |
| SCHEMBL20830062 | 0.82 | — | — | |
| SCHEMBL17972404 | 0.78 | PLA2G2A (0.44) | PLA2G2AS1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL15948786 | 0.76 | CTSK (0.37) | — | |
| SCHEMBL20830178 | 0.71 | PGD (0.36) | S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL17174995 | 0.70 | CNR1 (0.36) | PLA2G2A | |
| SCHEMBL17174997 | 0.69 | DAGLA (0.37) | PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | PLA2G2A 1701/4885S1PR1 1296/4885S1PR3 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.